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Abstract: The coexistence of upper airways disease with chronic obstructive pulmonary disease 
(COPD) is not well documented. The aim of this research was to assess sino-nasal inflammation 
in COPD by various tools, and look for the impact on quality of life, relation to smoking, disease 
severity and systemic inflammation. Current and ex-smokers with COPD (n = 42) and healthy 
never-smokers (n = 21) were included in this study. COPD severity was assessed by GOLD 
criteria and BODE index. Markers of systemic inflammation were measured. Nasal symptoms 
and general quality of life were assessed using the questionnaires; sino-nasal questionnaire 
(SNAQ-11) and St. George's Respiratory Questionnaire (SGRQ). Nasal endoscopy and saccharine 
test were performed. Nasal lavages were collected for cytological examination and eicosanoids 
(cysteinyl leukotrienes, leukotriene B4, 8-isoprostane). Symptoms and endoscopic scores were 
higher in COPD (P  0.0001). Only SGRQ symptoms subscore correlated with SNAQ-11 
(r = 0.34, P = 0.035). Mucociliary clearance was impaired only in current smokers (9.91 ± 0.49 
versus 13.12 ± 0.68 minutes, P  0.001). 8-isoprostane was higher in COPD smokers compared 
to the controls (0.17 ± 0.04 versus 0.34 ± 0.09 pg/g protein, P  0.05). Endoscopic score and 
mucociliary of impairment patients who currently smoked cigarettes correlated with concentra-
tions of 8-isoprostane. None of the parameters correlated with disease severity and markers of 
systemic inflammation. We provide evidence of upper airways disease in COPD, which appears 
to be related more to patients who currently smoke than to disease severity.
Keywords: chronic obstructive pulmonary disease, eicosanoids, nasal lavage, rhinitis, smoking, 
upper airways disease
Introduction
The close relationship between asthma, allergic and nonallergic rhinosinusitis and nasal 
polyps has been acknowledged for many years. It has been estimated, that approximately 
90% of allergic asthmatics suffer from rhinitis, and around 30% of rhinitis patients 
suffer from asthma.1 The theory of “united airway” or “common airway disease” 
has been formulated and described in several review papers and monographs.2–4 For 
many years the problem of upper airways pathology in patients suffering from chronic 
obstructive pulmonary disease (COPD) has, until late 1990s, rarely been a subject of 
investigation.
Cigarette smoke, the most important risk factor for COPD, has a devastating 
potential for nasal mucosa, and may cause several nasal symptoms,5 impairment 
of mucociliary function,6 pathological signs of mucosal inflammation,7 and other 
changes.8 Montnémery and colleagues9 reported a prevalence of respiratory symptoms 
in about 40% of Swedes self-reporting chronic bronchitis or emphysema, compared International Journal of COPD 2010:5 108
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decongestants, drugs known to induce rhinitis in the 
last 4 weeks.
e.  Domiciliary oxygen therapy and noninvasive ventilation.
f.  Pregnancy and lactation.
g.  Severe anatomical changes of nasal cavities.
h.  Alcohol and drug abuse.
Asthma was excluded and COPD was confirmed 
on the basis of the lack of typical asthmatic symptoms, 
negative history of allergy, negative skin prick tests, late 
disease onset (40 years of age), the presence of severe 
smoking history (20 pack-years) and the presence of 
irreversible obstruction in spirometry. According to GOLD 
criteria,12 stage I was diagnosed in four patients, stage 
II in 11 patients, stage III in 19 patients and stage IV in 
eight patients. The group was divided into mild/moderate 
(stage I plus II) and severe/very severe (stage III plus IV). 
Patients were also divided into subgroups of present and 
exsmokers.
Control group
The control group consisted of 21 healthy subjects who have 
never smoked (10 females, age 59 ± 9 years). The substan-
tial impact of passive smoking was disregarded. Exclusion 
criteria for this group included:
a.  COPD.
b.  Chronic lower and upper airways diseases (including 
asthma and allergy).
c.  Infection in the last 4 weeks.
d.  Systemic diseases (eg, diabetes).
e.  Necessity of any chronic pharmacological treatment.
f.  Smoking (ever).
All participants signed informed consent. The study was 
approved by the Ethics Committee at The Medical University 
of Lodz (consent number RNN 1307 KE).
Nasal symptoms
Nasal symptoms were assessed by a specific  validated Sino-
Nasal Assessment Questionnaire (SNAQ-11), consisting of 
11 nose, sinus, and general items.13 Total score of 0 was the 
lowest and 80 was the highest possible.
Quality of life
Quality of life was estimated by a validated, self-administered, 
airway disease-specific and commonly used St. George’s 
Respiratory Questionnaire (SGRQ)14 which consisted of 50 
items grouped into three subscales: symptoms, activity and 
to approximately 30% of the general population; whereas 
other authors report a much higher prevalence, reaching as 
much as 88%.10 Rhinosinusitis in COPD has been studied 
by few authors; only in the context of: nasal symptoms 
and their impact on quality of life; character of mucosal 
inflammation; and the relationship of upper airway disease 
to smoking and disease severity. So far, not all results are 
conclusive. For example, it is still not clear, how the severity 
of COPD, which according to many authors reflects the 
degree of lower airways inflammation,11 influences the degree 
of inflammation in the nose. It is also not known, what the 
relationship is between rhinosinusitis and systemic inflam-
mation in COPD. Finally, new noninvasive methods should 
be applied to assess upper airway inflammation in COPD. 
Therefore, the aim of this study was to test:
1.  Whether nasal symptoms, mucosal changes, and muco-
ciliary clearance are different in COPD when compared 
to healthy nonsmokers?
2.  What is the impact of nasal symptoms on general quality 
of life?
3.  Whether upper airway inflammation in COPD can be 
characterized by changes in nasal lavage cellular pattern 
and increased concentrations of eicosanoids?
4.  What is the relationship between all measured parameters 
with smoking?
5.  What is the relationship between all measured parameters 
with disease severity?




Forty-two patients with COPD (13 females), age 50–84 years 
(mean ± standard deviation [SD] = 65 ± 8 years). We defined 
the following inclusion/exclusion criteria:
1.  Inclusion criteria:
a.  Diagnosis of COPD, forced expiratory volume/forced 
vital capacity (FEV1/FVC)  70%.
b.  Age  40.
2.  Exclusion criteria:
a.  Asthma and other chronic respiratory disorders.
b.  Infection in the last 4 weeks.
c.  Severe diseases that could influence the results of 
examinations (eg, cancer, uncompensated diabetes, 
tuberculosis).
d.  Patients treated with H1 receptor inhibitors, intra-
nasal and systemic steroids, local and systemic International Journal of COPD 2010:5 109
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impact on health. SGRQ scores were calculated with the help 
of score calculator.15
Spirometry
Spirometry was measured according to European Respira-
tory Society (ERS) criteria,16 on computer-based spirometer 
(Jaeger, Germany). FEV1 and FVC results were presented 
as a % of predicted values. FEV1/FVC was calculated from 
best values achieved.
BODE index
BODE index (Body mass index; Obstruction; Dyspnea; 
Exercise capacity) was calculated, as previously described.17 
The lowest number of scores is 0, and the highest is 10. The 
higher number indicates the worse prognosis of COPD.17
Routine laboratory tests
Peripheral blood was taken for C-reactive protein (CRP), eryth-
rocyte sedimentation rate (ESR), morphology with estimation 
of white blood count (WBC) and hematocrit (HTC). Arterial-
ized capillary blood from a fingertip was taken for blood gas 
analysis. Electrocardiogram (ECG) and chest X-ray were per-
formed seeking signs of cor pulmonale. In case of the presence 
of such abnormalities in patients with FEV1 between 30%–50% 
predicted, they were qualified as COPD stage IV .12
Nasal endoscopic examination
Nasal endoscopic examination was performed with a fiber-
scope with external diameter of 4 mm (Pentax, Japan). 
Mucosal changes were estimated according to modified 
Lund-Kennedy scale.18 Each nasal cavity was examined sepa-
rately and the following scoring system was applied: edema 
(0–2); polyps (0–1); discharge (0–3); and hyperemia (0–1). 
The possible number of points ranged from 0 to 14.
Saccharine test
A saccharine test was applied for estimation of mucociliary 
clearance.19 The time (in minutes) from application of saccharine 
crystals on the anterior edge of inferior nasal conchae to first feel-
ing of sweet taste was a measure of the mucociliary clearance. 
Fifteen minutes was taken as a higher limit of normal values.
Nasal lavage
Nasal lavage (NAL) was collected as described.20 It was per-
formed in a sitting position, with the head bowed to the chest. 
Six milliliters of 0.9% NaCl was poured to a nasal cavity by a 
specifically adopted syringe with a rubber seal around the tip. 
The syringe was kept in position, closing a nasal cavity for 
5 minutes, with the head still bowed to the chest. During this 
period patients breathed through the mouth. Afterwards the 
saline was aspirated to a syringe. The procedure was the repeated 
in the second nasal cavity. Recovery was always above 80%. 
Collected fluid was centrifuged for 10 minutes (1600 rotations/
minute). The supernatant was collected by pipette, and stored at 
−80°C, until measurement of eicosanoids could be undertaken. 
The pellet was suspended in 1 mL of phosphate-buffered saline 
(PBS) for further cytological examination.
Cytological examination of NAL
The cytospin slides were stained with May–Grünwald–
Giemsa stain. The percentage of neutrophils, macrophages, 
lymphocytes, eosinophils, basophils, and epithelial cells was 
then calculated.
Measurement of immunoreactive 
eicosanoids
Cysteinyl leukotrienes (CysLTs), leukotriene B4 (LTB4) and 
8-isoprostane (8-IP) concentrations in NAL were measured 
by a specific enzyme immunoassay (EIA) kit (Cayman Chem-
ical, Ann Arbour, MI). The detection limits were: 13 pg/mL 
for cysLT and LTB4 and 5 pg/mL for 8-IP. Levels of measured 
mediators below the detection limit were arbitrarily assumed 
to be half of the detection limit value. Finally, measured 
concentrations of eicosanoids were standardized for protein 
concentrations and expressed as pg/g protein.
Statistical analysis
Data with a normal distribution were expressed as 
mean ± standard error of means (SEM). Medians with 25 
and 75 percentile were provided when data were not nor-
mally distributed. Unpaired t-test (for normally distributed 
data) or the Mann–Whitney test (for data without normal 
distribution) was used. When more than two groups were 
compared (controls versus COPD. All versus: smokers; 
exsmokers; or COPD stages), one-way ANOVA and Bonfer-
roni post-test (for data with Gaussian distribution) or the 
Kruskall–Wallis followed by Dunn’s multiple comparison 
test (for data without normal distribution), were used. The 
Spearman test (nonparametric) or Pearson test (for data 
with normal distribution) were applied to assess correla-
tions. The P value  0.05 was assumed as statistically 
significant.
Results
The characteristics of both the study and control groups are 
provided in Table 1.International Journal of COPD 2010:5 110
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Table 1 Characteristics of the study and control groups
  Control group COPD all COPD I/II COPD III/IV
Number 21 42 16 26
Females [%] 10 (48) 13 (31) 4 (25) 9 (35)
Age [years] 59 ± 9 68 ± 8 66 ± 9 64 ± 8
FEV1 [% predicted] 104.2 ± 2.7 50.2 ± 19.9 69.7 ± 17.4 38.2 + 8.6
FVC [% predicted] 108.6 ± 3.2 75.4 ± 18.4 88.0 ± 17.1 67.1 ± 14.2
FEV1/FVC [%] 81.2 ± 1.1 50.6 ± 13.2 60.6 ± 6.9 46.2 ± 10.5
Pack-years 0 35.8 ± 13.7 35.9 ± 11.2 35.7 ± 15.3
Active smokers No [%] 0 (0) 13 (31) 4 (25) 9 (35)
Cigarettes daily 0 2.6 ± 4.9 2.6 ± 5.7 2.6 ± 4.5
COPD duration [years] NA 6.7 ± 0.6 6.8 ± 0.9 6.7 ± 0.7
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume; FVC, forced vital capacity.
COPD versus healthy subjects: nasal 
symptoms, mucosal changes,  
mucociliary clearance
The total score in SNAQ-11 questionnaire was higher in 
COPD patients than in the control group: 3.38 ± 0.80 versus 
23.93 ± 1.94, P  0.0001, Figure 1. Only one patient did not 
report any symptoms (2.3% versus 28.6% for controls). The 
most frequent symptom in COPD was cough (92.3% of all 
patients versus none in controls). Other frequent symptoms 
were: lack of good nights/tiredness/fatigue; runny nose; nasal 
congestion, blocked nose and sneezing. The least frequent 
symptoms were: facial pain/pressure and earache/ear fullness. 
Results are presented in Table 2.
The number of scores in the endoscopic examination was 
higher in COPD than in controls (median, 25–75th percen-

















Figure 1 The results of SNAQ-11 in healthy controls and COPD patients
Abbreviations: COPD, chronic obstructive pulmonary disease; SNAQ-11, Sino-Nasal Assessment Questionnaire.International Journal of COPD 2010:5 111
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Table 2 Results of SNAQ-11 and correlations of sino-nasal symptoms with SGRQ results in all COPD patients
  Item % all answers  SGRQ total SGRQ symptoms SGRQ activity SGRQ impact
  1 Blocked nose 76.9 NS r = 0.33  
P = 0.04
NS NS
  2 Nasal congestion/stuffy nose 76.9 NS r = 0.38  
P = 0.02
NS NS
  3 Facial pain/pressure 20.5 NS NS NS NS
  4 Runny nose/anterior nasal discharge 79.5 NS NS NS NS
  5 Postnasal discharge 56.4 NS NS NS NS
  6 Sneezing 76.9 NS NS NS NS
  7 Cough 92.3 NS NS NS NS
  8 Reduced/altered smell 35.9 NS NS NS NS
  9 Headache 64.1 NS NS NS NS
10 Earache/ear fullness 43.6 r = 0.37  
P = 0.02
r = 0.38 
P = 0.02
r = 0.35 
P 0.05
r = 0.35 
P = 0.04
11 Lack of good nights  
sleep/tiredness/fatigue
82.1 r = 0.38  
P = 0.02
NS r = 0.34 
P = 0.04
r = 0.38 
P = 0.02
All 97.6 NS r = 0.39  
P = 0.01
NS NS
   All – 7 (without cough)  97.6  NS  r = 0.35  
P = 0.03
NS  NS 
Abbreviations: COPD, chronic obstructive pulmonary disease. NS, not significant; SGRQ, St. George Respiratory Questionnaire; SNAQ-11, Sino-Nasal 
Assessment Questionnaire.
Time from the application of saccharine crystals to the 
first feeling of a sweet taste was longer in all COPD groups 
but did not reach statistical significance (9.91 ± 0.49 versus 
13.12 ± 0.68, P  0.05, Figure 3).
Positive correlations were found between the SNAQ-11 
questionnaire and endoscopic scoring (r = 0.58, P  0.0001, 
Figure 4 A) and mucociliary clearance time (r = 0.51, 
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Figure 2 The results of endoscopic scores in healthy controls, all COPD patients, COPD active smokers, and COPD ex-smokers.
Abbreviation: COPD, chronic obstructive pulmonary disese.International Journal of COPD 2010:5 112
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Figure 3 The results of saccharine test (in minutes) in healthy controls, all COPD patients, COPD active smokers, and COPD exsmokers.
Abbreviation: COPD, chronic obstructive pulmonary disease.
Nasal symptoms and general quality of life
Nasal symptoms (SNAQ-11) did not correlate with the total 
scores of SGRQ, activity, and impact subscores, regardless the 
cough item was calculated or not. Only weak correlation was 
found with symptoms subscore (r = 0.34, P = 0.035, and when 
cough was subtracted: r = 0.36, P = 0.025). This correlation 
was related to blocked nose, nasal congestion/stuffy nose, and 
earache/ear fullness, but not to cough. No correlations were 
found between SGRQ total scores or subscores with endoscopic 
scoring and saccharine test results. See Table 2 for results.
COPD vs controls: nasal lavage cells 
and eicosanoids
There were no significant differences in nasal lavage cells 
percentage between COPD and controls. There was only a 
tendency towards higher values of lymphocytes in COPD: 
10.3 ± 2.0 versus 16.8 ± 2.3 (P = 0.067).
Nasal 8-IP were not higher in COPD compared to control 
values (median, 25–75 percentile): 0.13, 0.08–0.21 versus 
0.13, 0.11–0.31 pg/g protein (P = 0.39). Similarly, there 
were no differences in cysLT 0.36, 0.15–0.59 versus 0.30, 
0.22–0.6 (P = 0.33) and LTB4 0.57, 0.29–1.5 versus 0.6, 
0.19–1.01 pg/g protein (P = 0.10).
There were no correlations between nasal eicosanoids 
and percentage of nasal cells. Eicosanoids were mutually, 
strongly correlated: 8-IP versus LTB4 (r = 0.59, P  0.0001), 
8-IP versus cysLT (r = 0.6, P  0.0001), LTB4 versus cysLT 
(r = 0.61, P  0.0001).
Influence of smoking
Symptoms were not different between smokers and 
exsmokers with COPD. There were no correlations between 
symptom scores and cumulative smoking consumption 
(pack-years) (r = −0.06, P = 0.69).
Endoscopic scores were higher in smokers (median, 
25–75th percentile: 6.25, 4.75–8.0) than in controls (0, 0–1.0, 
P  0.01) and in exsmokers (2.0, 1.5–4.0, P  0.05), 
Figure 2. With smokers, a correlation was found between 
endoscopic scores and daily cigarettes consumption (r = 0.60, 
P  0.0001).
The saccharine test revealed longer mucociliary clear-
ance time in COPD smokers than in controls (9.91 ± 0.49 
versus 16.31 ± 1.57 minutes, P  0.001) and in exsmokers 
(11.21 ± 0.48, P  0.01), Figure 3. Saccharine test results corre-
lated with actual cigarette consumption (r = 0.43, P = 0.005).
NAL cells were not different between smokers and 
exsmokers and between smokers and controls. 
Nasal 8-IP concentrations were higher in COPD smokers 
than in controls: 0.17 ± 0.04 versus 0.34 ± 0.09, P = 0.049, 
Figure 5. Positive correlation was found with actual cigarette International Journal of COPD 2010:5 113
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Figure 4 Correlations between SNAQ-11 results with endoscopic score (A) and saccharine test (B) in all COPD patients.
Abbreviations: COPD, chronic obstructive pulmonary disease; SNAQ-11, Sino-Nasal Assessment Questionnaire.International Journal of COPD 2010:5 114
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Figure 5 Concentrations of 8-isoprostane (8-IP) in nasal lavage (pg/g protein) in healthy subjects, COPD smokers, and exsmokers.
Abbreviation: COPD, chronic obstructive pulmonary disease.
consumption (r = 0.37, P = 0.02) and negative with time from 
smoking cessation (r = 0.35, P = 0.02).
COPD severity and rhinosinusitis
Symptoms, endoscopic score, saccharine test results, cellular 
profile of NAL, NAL eicosanoids were not different between 
GOLD stages. There were no correlations of these parameters 
with FEV1, BODE index and its components, partial pressure 
of oxygen in arterial blood (Pa O2) and PaCO2.
Markers of systemic inflammation  
and rhinosinusitis
No correlations were found between SNAQ-11 score, 
  endoscopic score, saccharine test results, cellular profile of 
NAL, NAL eicosanoids, and CRP, ESR or WBC.
Discussion
Nasal symptoms, mucosal changes,  
and mucociliary clearance in COPD
Although our study group was relatively small, the frequency 
of symptomatic patients close to 98% (at least one symptom) 
is unequivocal, and fully consistent with the results of 
  others.9,10 The structure of symptoms seems to be quite 
  significant for this group of patients. The most frequent 
symptoms, cough and lack of good night’s sleep/tiredness/
fatigue may be related more to COPD rather than to upper 
airway disease. When these symptoms are excluded, the 
typical rhinitis symptoms become most prevalent. The least 
frequent symptoms are related to sinus and ear. The same 
symptom structure was reported by Montnémery and col-
leagues,9 although assessed by different methods.
A strong positive correlation between SNAQ-11 scores 
and endoscopic scores was found in our study and is in 
opposition to the results of Tahamiler and colleagues,21 who 
found that 75% of patients with symptom-based diagnosis 
of chronic nonallergic rhino-sinusitis had no endoscopic 
pathology. Similar doubts on the value of symptom-based 
diagnosis of chronic rhinosinusitis have been raised by 
  others.22 We believe, that the good correlation of symptom 
and endoscopic scores in our study may be explained by 
homogenous population of patients, who suffered from a 
disease (COPD) with known high prevalence of rhinosinus-
itis, and not in the general non-predefined population, as it 
was in case of cited studies.
Mucociliary clearance time measured by the saccharine 
test may be treated as another objective measure char-
acterizing rhinitis in COPD. It reflects one of the main 
physiologic features of upper and lower airway inflamma-
tion in smoking-related COPD. There may be a variety of International Journal of COPD 2010:5 115
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mechanisms involved in mucociliary clearance impairment 
in COPD, including decrease of cilia density on the nasal 
epithelium, increase of mucus viscosity, ion transport dis-
turbances or impairment of cilia activity.23–25
Nasal symptoms and quality of life
Some authors suggest, that upper airway symptoms impair 
the overall quality of life in COPD patients.10 There is even 
speculation that treatment of rhinosinusitis may substan-
tially improve quality of life of these patients.26 Hurst and 
colleagues10 reported decreased quality of life assessed by 
Sino-Nasal Outcome Test (SNOT-20) questionnaire, which is 
specific for rhinosinusitis but contains general items evaluat-
ing quality of life. Based on their results it was concluded, that 
rhino-sinal disease impairs quality of life of these patients. 
However, no correlation was found between SNOT-20 and 
SGRQ, which led the authors to suggest, that these effects 
may not be detected by currently available tools (SGRQ), 
which focus mainly on lower respiratory tract symptoms. 
Our results show a positive correlation with the symptoms 
subscale of SGRQ, suggesting that the more symptomatic 
COPD, the more symptomatic rhinosinusitis. Total, activity 
and impact scores were not correlated. The analysis of the 
particular items of SNAQ-11 questionnaire indicated, that 
blocked nose and nasal congestion may be responsible for 
this relationship. Earache/earfulness influenced all parts of 
SGRQ, but this symptom was relatively rare. More impor-
tant is the analysis of symptoms which are non-specific for 
upper airway disease, like cough and disturbed nights sleep, 
tiredness, fatigue. The latter was a frequent complaint and 
correlated with total, activity and impact subscores, but not 
with symptoms. The most frequent item, cough, was not cor-
related with any of SGRQ subscores and the subtraction of 
this symptom did not result in losing statistical significance 
of the above mentioned correlations. Therefore we conclude, 
that rhino-sinal disease influence COPD-related symptoms 
but not the general quality of life assessed by SGRQ.
Nasal lavage cells and eicosanoids
Providing nasal mucosal changes reflect bronchial inflam-
mation in COPD, we should expect that the most prominent 
cells in nasal lavages are neutrophils. In our study we have 
not found any differences in the percentage of neutrophils. 
Also there were no differences in relation to other cell types 
between COPD and healthy nonsmokers. In the study of 
Nihlén and colleagues,27 concentrations of myeloperoxidase 
(MPO) in NAL, a marker of neutrophil activity, was not higher 
in COPD, but MPO levels exhibited a greater increase from 
baseline at histamine challenge in these patients compared 
to controls. Moreover, in patients’ reporting nasal symptoms 
this increase was especially high. These observations provide 
only indirect proof for the involvement of neutrophils. More 
direct evidence of neutrophils involvement was provided by 
Vachier and colleagues,28 who found increased numbers of 
neutrophils in nasal biopsies of smokers with COPD, com-
pared to smokers without COPD and healthy subjects. In this 
exclusive study (the only one based on nasal mucosal biopsy) 
increased number of CD8 T lymphocytes was also confirmed. 
Not surprisingly, these features of nasal inflammation were 
concordant with bronchial inflammation, and confirmed the 
pan-airway disease idea in COPD.
To the best of our knowledge, this study is the first to 
apply eicosanoids in nasal lavages to assess upper airway 
inflammation in COPD. We measured cysteinyl leukotrienes 
(cysLT) – a marker of eosinophil activity, leukotrienes B4 
(LTB4) – a marker of neutrophil activity, and 8-isoprostane 
(8-IP), – a product of nonenzymatic peroxidation of arachi-
donic acid, which has been proven to be a reliable marker 
of lipid peroxidation.29 These markers were measured in 
broncholaveolar lavage fluid, induced sputum or exhaled 
breath condensate (EBC) of asthma and COPD patients. 
For example, sputum 8-IP is elevated in asymptomatic 
smokers,30 LTB4 in sputum/EBC are elevated in stable31 and 
exacerbated COPD,32 and exhaled breath cysLT concentra-
tions are elevated in asthma.33 Unfortunately, we could not 
present any differences in concentrations of NAL eicosanoids 
between COPD and control subjects. Also, eicosanoids were 
not correlated with nasal lavage cells, specifically there were 
no correlations between NAL neutrophils and LTB4 or 8-IP 
(neutrophils are a source of reactive oxygen species and 
neutrophillic inflammation is linked to oxidative stress). In 
view of our results it is probable, that only biopsy of nasal 
mucosa could prove the presence of the typical features of 
COPD-like inflammation in the nose. Although the biopsy 
of nasal mucosa was included in the primary protocol of our 
study and we received consent from ethical committee to 
perform biopsy, we were forced to resign from this procedure 
due to high rate of patients’ refusals.
Rhinosinusitis and smoking
In epidemiological studies COPD and rhinitis are related 
to common predisposing factors: smoking; age; and sex.34 
We provide data showing, that active smokers with COPD 
have more intensive inflammation as assessed by endoscopic 
scores and the saccharine test. Prolonged mucociliary clear-
ance in COPD smokers in our study is in agreement with International Journal of COPD 2010:5 116
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the results of Stanley and colleagues,6 who also found, that 
decreased mucociliary clearance in smokers is not related to 
decreased ciliary beat frequency. No differences were found 
between smokers and ex-smokers or healthy never-smokers in 
the cellular content of NAL. We did not find any correlations 
between nasal cells (specifically neutrophils and eosinophils) 
and cumulative or current cigarette consumption. However, 
there was a difference between COPD smokers and healthy 
controls in nasal 8-IP concentration. Moreover, NAL 8-IP 
concentrations correlated positively with current smoking 
consumption. All these confirm the role of smoking in upper 
airway inflammation and suggest that in those who quit smok-
ing, some improvement of rhinosinusitis may be achieved. 
Smoking is a well known trigger of oxidative stress. Smoke 
itself is a rich source of free radicals; various oxidants may be 
released from activated inflammatory cells, like neutrophils 
and eosinophils.28 Arachidonic acid, a natural substrate for 
8-IP, may be released from cellular membranes of injured epi-
thelia. As suggested before, evidence of less intensive rhinitis 
in COPD patients who managed to quit smoking compared 
to smoking COPD subjects–regardless of age, cumulative 
cigarette consumption and COPD severity–suggests partial 
reversibility of upper airway disease. It has been acknowl-
edged for years, that smoking cessation improves symptoms 
and slows lung function decline in COPD.12 Lapperre and 
colleagues reported that the infiltration of bronchial mucosa 
in COPD patients with CD8+ T lymphocytes decreases gradu-
ally with time after smoking cessation.35 Therefore it may 
be speculated, that smoking cessation may decrease upper 
airway inflammation.
In order to fully acknowledge the influence of smoking 
on rhinosinusitis in COPD, our results should have been 
compared with a group of non-COPD smokers. The lack of 
such a control group is a limitation of our study.
Rhinosinusitis and COPD severity
The literature provides ambiguous data on this subject. Hurst 
and colleagues reported that decreased nasal patency measured 
by acoustic rhinometry is proportional to the degree of airflow 
obstruction.36 Although we have not used any methods to objec-
tively measure nasal patency, none of the measured parameters 
characterizing rhinosinusitis were correlated with FEV1, BODE 
index and its components. The same group of authors neglects the 
relationship between nasal inflammatory markers and FEV1.37
Rhinosinusitis and systemic inflammation
The question arises, whether upper airway disease is one 
of the elements of COPD-related systemic inflammatory 
disease. We correlated all measured parameters with markers 
of systemic inflammation, such as CRP, ESR or WBC, and 
did not find any correlations. Similar negative results were 
presented by others in stable disease in relation to serum 
IL-6,37 and during COPD exacerbations, when serum CRP 
and IL-6 were measured.38
Conclusions
1.  Our results confirm the high prevalence of rhinosinusitis 
in COPD
2.  We could not provide data on the substantial impact 
of rhinosinusitis symptoms on general quality of life 
assessed by SGRQ
3.  Nasal lavage cellular pattern and eicosanoids do not dif-
ferentiate COPD patients from healthy subjects
4.  Active smoking is connected with more severe upper 
airway inflammation
5.  Upper airway disease is not strictly related to COPD 
severity
6.  No evidence was found for the relationship between nasal 
symptoms and other features of upper airway disease with 
systemic inflammation.
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